Although several small-molecule drugs can slow the growth of kidney cysts, the only approved medication that offers measurable benefit often comes with serious side effects affecting kidney tissue, Weimbs said. Antibodies made in the lab could, in theory, provide far more precise treatment. However, the most widely used antibodies—immunoglobulin G (IgG)—are simply too large to penetrate the cysts where the disease actually unfolds.

Figure 1. Antibody Slips Inside Kidney Cysts to Shut Them Down

“IgG antibodies work extremely well in cancer therapy,” Weimbs explained. “But they can’t cross cellular barriers, which means they never reach the inside of the cysts.” That limitation is critical, because the cyst interior—an enclosed space lined with epithelial cells—is where pathological signaling is actively sustained. Figure 1 shows Antibody Slips Inside Kidney Cysts to Shut Them Down.

According to Weimbs, many cyst-lining cells produce growth factors and release them into the cyst fluid. These molecules then bind back to the same cells or nearby ones, continuously stimulating growth in a self-reinforcing loop. “It becomes a never-ending cycle of activation,” he said. “Our idea was that by blocking either the growth factor itself or its receptor, we could interrupt this feedback loop and shut down the abnormal cell activity.”

A New Antibody Built to Reach Inside Kidney Cysts

The solution may lie in dimeric immunoglobulin A (dIgA), a monoclonal antibody capable of crossing epithelial barriers. In the body, dIgA is naturally secreted into mucus, saliva, and tears, where it serves as an early line of defense against invading pathogens. In a 2015 study, Weimbs and his colleagues proposed that dIgA could attach to polymeric immunoglobulin receptors on epithelial cells and be transported across the membrane into kidney cysts. Once inside, the antibody could directly target receptors that drive unchecked cyst growth.

Building on that earlier work, the new study confirms this strategy’s potential by successfully targeting one of the key drivers of cyst expansion: the mesenchymal-epithelial transition (cMET) receptor.

Engineering and Testing the Modified Antibody

To create the new antibody, the researchers reengineered IgG by modifying its DNA sequence to give it a different structural backbone, effectively converting it into dimeric immunoglobulin A (dIgA). They first confirmed that the redesigned antibody could recognize its intended receptor, then tested it in mouse models. The results showed that the antibody successfully penetrated kidney cysts and remained there.

The next challenge was determining whether the antibody could actually block the targeted growth factor receptor. “The key question was whether it could shut down that specific pathway,” Weimbs said. The experiments revealed a clear reduction in cMET activity, leading to decreased growth signaling in cyst-lining cells. Notably, the treatment triggered a “dramatic onset of apoptosis” in cyst epithelial cells while leaving healthy kidney tissue unaffected, with no detectable side effects.

Next Steps Toward Future PKD Therapies

Because the research is still in the preclinical phase, Weimbs emphasized that significant time and additional testing will be required before the approach could move toward human trials. Advancing the therapy will also require collaborators focused on polycystic kidney disease (PKD) and access to specialized facilities capable of developing and evaluating new antibody treatments.

As Weimbs explained, cyst fluid contains dozens of active growth factors, suggesting multiple possible therapeutic targets. Future studies could compare antibodies that block different growth factors or receptors side by side to determine which approach is most effective. Combining antibodies that target multiple receptors at once may also help slow—or potentially reverse—disease progression.

Source: SciTECHDaily

Cite this article:

Janani R (2025), Researchers Find Antibody That Enters Kidney Cysts and Switches Them Off, AnaTechMaz, pp. 636